- Advertisement -
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)—- $VYCT #ASTRO25–Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, announced that new data from the prospective, randomized integral biomarker BALANCE trial (NCT03371719) finds that the PAM50 molecular signature predicts which…
Click here to view the original article.
